----item----
version: 1
id: {90F7EDFD-CB66-43A7-B97B-EAA63DA44C01}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/08/13/Sarepta Forms Strategic Advisory Board
parent: {B23F589E-74E7-4CA3-9A57-5AB55E4AFD4B}
name: Sarepta Forms Strategic Advisory Board
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: ab751ccc-cb98-473b-8995-acca98864e94

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 38

Sarepta Forms Strategic Advisory Board
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 38

Sarepta Forms Strategic Advisory Board
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1548

<p>Sarepta Therapeutics Inc., a developer of RNA-targeted therapies, has formed a strategic and scientific advisory board (SSAB) with three key appointments: Dr Louis Kunkel, Dr Beverly Davidson, and Dr Jeffrey Chamberlain. The SSAB will work closely with Sarepta's management team to advance the company's platform technology in Duchene muscular dystrophy, identify multiple new applications for Sarepta's proprietary PMO chemistry in the neuromuscular rare disease and infectious disease areas, as well as provide insight on novel technologies to complement the company's pipeline.</p><p>Kunkel is currently a member of the division of genetics and genomics at Boston Children's Hospital. He is responsible for the identification of the gene and encoded protein, dystrophin, and has received numerous awards for scientific leadership and achievement and currently serves as the committee chair for the Muscular Dystrophy Association.</p><p>Davidson is director of the Raymond G Perelman Center for Cellular and Molecular Therapeutics and Arthur V. Meigs chair in pediatrics at Children's Hospital of Philadelphia; and professor in the department of pathology and laboratory medicine for Perelman School of Medicine at the University of Pennsylvania.</p><p>Finally, Chamberlain is currently a professor in the departments of neurology, medicine, and biochemistry; McCaw endowed chair in muscular dystrophy at the University of Washington; and director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center of Seattle.</p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 587

<p>Sarepta Therapeutics Inc., a developer of RNA-targeted therapies, has formed a strategic and scientific advisory board (SSAB) with three key appointments: Dr Louis Kunkel, Dr Beverly Davidson, and Dr Jeffrey Chamberlain. The SSAB will work closely with Sarepta's management team to advance the company's platform technology in Duchene muscular dystrophy, identify multiple new applications for Sarepta's proprietary PMO chemistry in the neuromuscular rare disease and infectious disease areas, as well as provide insight on novel technologies to complement the company's pipeline.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 38

Sarepta Forms Strategic Advisory Board
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150813T130000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150813T130000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150813T130000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029495
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 38

Sarepta Forms Strategic Advisory Board
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{090E9A04-9B4B-4986-8BAF-06A6B07B978D}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359848
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042434Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

ab751ccc-cb98-473b-8995-acca98864e94
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042434Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
